Breast Cancer Awareness Month
Kenbotek, which develops integrative oncology products based on cannabinoids and mushroom extracts, reports the results of a study in the CureResponse ex-vivo model in which the anti-cancer effectiveness of its integrative solution was tested on diseased breast cancer tissues. The study also examined the combined response of the integrative products with chemotherapy as well as the effect of the products on the various factors in the tumor environment, including the response of the cells of the immune system.
More in-
CureResponse’s platform for personalizing anti-cancer treatments is based on technology developed at the Weizmann Institute. The test has been approved by the Israeli Ministry of Health and the insurance companies and is used as an important tool by oncologists who attribute to it a high predictive ability for therapeutic success in patients. Kenbotek joined CureResponse after a number of senior oncologists in Israel clarified that positive results would be a positive indication for the success of the treatment in humans as well.
Preliminary results from the experiment on the patients’ tissues came back and confirmed the previous results of Kenbotek in cells and are an important step on the way to proving the effectiveness of the products in humans. Among the important findings, OncoRix products showed:
- Synergistic activity in combination with common chemotherapy treatment: increasing the anti-cancer effectiveness of chemotherapy given in low concentrations and significantly higher anti-cancer effectiveness than chemotherapy alone.
- The effect of the treatment on the cells of the immune system in the tumor environment that may indicate the activation of the immune cells in the tissue. The meaning of the results is that it is possible that in the future it will be possible to achieve increased efficiency of killing breast cancer cells while reducing the doses of chemotherapy needed, which is expected to significantly reduce the side effects as well, and allow for more are treated, since nowadays a dose reduction is sometimes required in view of the side effects of the anticancer drugs.
It is estimated that a significant proportion of breast cancer patients are already consuming medical cannabis at the same time as the drug treatment, with the aim of treating the symptoms of the tumor process and the side effects of the oncological treatments. OncoRix offers them a solution that will reduce the impact of the side effects and will also have a real potential to enhance the anti-cancer treatment itself.
Kenbotek’s integrative oncology product series was built on the basis of extensive literary information and its effectiveness was tested in a number of different research models. The cannabinoid products will be given in the form of Soft Gel and the mushroom extracts in the form of caplets, where a unique delivery system technology has also been incorporated into each of the solutions to improve the efficiency of the treatment. The products have been specially adapted to integrate into the current oncological treatment protocols, in parallel with the conventional drugs, under the regulation of medical cannabis.
The products are expected to start being sold in California in the coming months, under the OncoRix brand, with the first two solutions to be launched to support breast cancer patients and the pain associated with the tumor disease, and then the solutions for colon, pancreatic, lung and prostate cancer will also be launched. The solutions will be offered as part of a six-month program where the oncology patient will consume the integrative products at the same time as the conventional treatment. As part of the program, the patient will also be accompanied by a personal oncology nurse and professional advice from Kenbotek’s team of clinical experts.
At the same time as the commercial launch of the products, Kenbotek is expected to conduct a clinical-observational trial in California in which it will collect relevant information from the patients in order to test the combined treatment in humans. The results collected will be used by Kenbotek in its marketing efforts to penetrate the oncology market in California as well as in the construction of a personalization system which is currently in the development stages.
In the current experiment, cancer tumors were taken only from patients with breast cancer that expresses hormone receptors (luminal breast cancer), which is the most common of breast cancer tumors, and the combination with the common and accepted chemotherapy in the treatment protocol was tested. It should be noted that Kenbotek has previously shown different efficacy in other subtypes of breast cancer.
Kenbotek is currently working on finishing the production of the initial stock according to the local regulation in California, forming a team to manage the project in California and raising dedicated capital that will ensure a successful penetration of the local oncology market.
The CEO of Kenbotek, Elhanan Shaked, said: “This is another significant milestone on Kenbotek’s path to becoming a leader in the integrative oncology market. OncoRix products are intended for use as a combined chemotherapy treatment in several types of cancer, and are expected to be launched in the coming months in California, with the company’s goal being to set a new standard in the oncology industry.”
Prof. Tami Peretz, a senior oncologist, said: “A significant proportion of cancer patients are currently treated with cannabis at the same time as conventional treatment. The integrative products developed by Kenbotek are unique in that they are developed according to standards similar to those of the pharmaceutical industry and combine several active substances. The company’s products have demonstrated impressive activity and is very promising in cell cultures tested in the laboratory. Based on these experiments, there is room to start examining the possibility of combining the products in breast cancer patients as well.”
Dr. Yitzhak Angel, Kenbotek’s pharmacological consultant, said: “The strong synergistic effect shown by the products among themselves as well as in combination with chemotherapy on breast cancer tissues resulted in increased efficiency in killing cells. CureResponse’s unique experimental system enables a functional experiment in a 3D cell system where treatment can be personalized, thereby bringing us closer to the patients themselves. We draw encouragement from these results, which are another important milestone in proving the scientific feasibility of the products. We will continue to work to provide relief to the sick.”
Comments to the article(0):
Your response has been received and will be published subject to the system policy.
Thanks.
for a new comment
Your response was not sent due to a communication problem, please try again.
Return to comment